Astellas Pharma Inc. (ALPMY) Stock Overview
Explore Astellas Pharma Inc.’s financial performance, market position, analyst ratings, and future outlook.
Astellas Pharma Inc. (ALPMY)
Key Financials
Key Financials
Market Cap
23.7B
P/E Ratio
12.38
EPS (TTM)
$1.01
ROE
0.18%
ALPMY Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Astellas Pharma Inc. (ALPMY) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 36.91, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $14.50.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 12.38 and a market capitalization of 23.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.